Adage Capital Partners’s Kymera Therapeutics KYMR Stock Holding History

Adage Capital Partners’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9M	Sell	200,000 -135,000	-40%	-$11.6M	0.03%	457
2026 Q1	$27.9M	Sell	335,000 -95,000	-22%	-$7.52M	0.04%	383
2025 Q4	$33.5M	Buy	430,000 +192,000	+81%	+$13M	0.05%	343
2025 Q3	$13.5M	Sell	238,000 -66,200	-22%	-$2.99M	0.02%	573
2025 Q2	$13.3M	Buy	+304,200	New	+$10.5M	0.02%	555
2022 Q2	–	Sell	-180,000	Closed	-$7.62M	–	1116
2022 Q1	$7.62M	Sell	180,000 -25,000	-12%	-$1.06M	0.01%	768
2021 Q4	$13M	Sell	205,000 -45,000	-18%	-$2.62M	0.02%	624
2021 Q3	$14.7M	Buy	250,000 +150,000	+150%	+$8.7M	0.03%	573
2021 Q2	$4.85M	Hold	100,000	–	–	0.01%	830
2021 Q1	$3.89M	Hold	100,000	–	–	0.01%	823
2020 Q4	$6.2M	Sell	100,000 -150,000	-60%	-$7.32M	0.01%	665
2020 Q3	$8.08M	Buy	+250,000	New	+$7.63M	0.02%	563

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Adage Capital Partners's KYMR Position: Q2 2026 in Review

Adage Capital Partners reduced its Kymera Therapeutics (KYMR) stake by 40% in Q2 2026, selling an estimated $11.6M and leaving 200,000 shares worth $22.9M. The position accounts for 0.03% of the portfolio, ranked #457.

Adage Capital Partners first reported a position in KYMR in Q3 2020 and has held it in 12 quarters since. The position peaked at $33.5M in Q4 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Adage Capital Partners held 200,000 shares of Kymera Therapeutics worth $22.9M as of Q2 2026.
Adage Capital Partners sold 135,000 Kymera Therapeutics shares in Q2 2026, an estimated $11.6M.
Kymera Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #457 holding.
Adage Capital Partners first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 12 quarters since.
Adage Capital Partners's Kymera Therapeutics position peaked at $33.5M in Q4 2025.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.